These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044 [TBL] [Abstract][Full Text] [Related]
4. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Villaruz LC; Socinski MA Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099 [TBL] [Abstract][Full Text] [Related]
5. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. Liang W; Wu X; Hong S; Zhang Y; Kang S; Fang W; Qin T; Huang Y; Zhao H; Zhang L PLoS One; 2014; 9(10):e109757. PubMed ID: 25329056 [TBL] [Abstract][Full Text] [Related]
7. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Ellis PM; Al-Saleh K Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734 [TBL] [Abstract][Full Text] [Related]
8. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548 [TBL] [Abstract][Full Text] [Related]
9. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Kurzrock R; Stewart DJ Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520 [TBL] [Abstract][Full Text] [Related]
10. Targeting blood vessels for the treatment of non-small cell lung cancer. Amir E; Hughes S; Blackhall F; Thatcher N; Ostoros G; Timar J; Tovari J; Kovacs G; Dome B Curr Cancer Drug Targets; 2008 Aug; 8(5):392-403. PubMed ID: 18690845 [TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Scagliotti G; Govindan R Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383 [TBL] [Abstract][Full Text] [Related]
12. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment. Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742 [TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenics: Their Value in Lung Cancer Therapy. Janning M; Loges S Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. Huang Y; Carbone DP Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052 [TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of non-small-cell lung cancer. Rashdan S; Hanna N Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846 [TBL] [Abstract][Full Text] [Related]
17. Nintedanib in non-small cell lung cancer: from preclinical to approval. Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy in nonsmall cell lung cancer. Gutierrez M; Giaccone G Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767 [TBL] [Abstract][Full Text] [Related]